1 hr ago

Moderna mRNA Flu Vaccine Shows Nearly 30% Better Protection

Moderna mRNA Flu Vaccine Shows Nearly 30% Better Protection
New mRNA Flu Shot In US Offers Nearly 30% More Protection For Adults 50+ · timesnownews.com

Scientists tested a new flu vaccine for adults aged 50 and older.

The vaccine is called MFLUSIVA.

It uses mRNA technology.

In a large Phase 3 study, it provided nearly 30% more protection than a standard-dose flu shot.

Moderna makes the vaccine.

The U.S. Food and Drug Administration approved it in August 2026.

It is meant to protect against flu strains included in the vaccine.

The approval applies to adults who are at least 50 years old.

Key facts

Vaccine
MFLUSIVA
Manufacturer
Moderna
Technology
mRNA-based influenza vaccine
Trial
Large Phase 3 trial
Protection result
Nearly 30% better protection than a standard-dose flu vaccine
Approved age group
Adults aged 50 and older
Approval date
August 2026
Approving authority
U.S. Food and Drug Administration

Sources

Related news